pharma news today obesity drugs glp-1 september 2025 Agonists Weight Loss Market Report, 2025-2030 Americans turn to risky unregulated
Description
116 Study details | Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and diet in inflammatory bowel disease (IBD) patients | ClinicalTrials.gov
[DOI] [PubMed] [Google Scholar] 190.Gibson G.E., Sheu K.F., Blass J.P., Baker A., Carlson K.C., Harding B., Perrino P
( 10.2337/dc14-1958) [DOI] [PubMed] [Google Scholar] Ludvik B Giorgino F Jodar E Frias JP Fernandez Lando L Brown K Bray R & Rodriguez
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
This therapy may not be appropriate for everyone
Super quick ordering and delivery
